Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs

被引:25
|
作者
Leung, S [1 ]
Bendayan, R [1 ]
机构
[1] Univ Toronto, Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 2S2, Canada
关键词
P-glycoprotein; dideoxynucleoside analogs; human immunodeficiency virus 1; transport; renal;
D O I
10.1139/cjpp-77-8-625
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
dP-glycoprotein (P-gp), the MDR1 multidrug transporter, is known to be expressed in several human organs and tissues, including the apical membrane of the renal proximal tubular cells. It has been reported that human immunodeficiency virus 1 (HIV-1) can trigger the expression of P-gp in cultured cells (i.e., H9, a T-lymphocyte cell line, and U937, a monocyte cell line), which may render the cells resistant to antiretrovirals. Since multiple membrane transport systems (i.e., organic cation, organic anion, and nucleoside systems) can be involved in the renal tubular transport of dideoxynucleoside analog drugs (DADs) (i.e., zidovudine and zalcitabine), we have questioned if P-gp is involved in the renal transport of DADs. Chinese hamster ovary colchicine-resistant cells (CH(R)C5), a cell line that is well known to highly express P-gp, and continuous renal epithelial cell lines (LLC-PK1 and OK), which have also been shown to express P-gp, were used. The accumulation of [H-3]vinblastine (20 nM), an established P-gp substrate, by the monolayer cells was significantly enhanced in the presence of two P-gp inhibitors (i.e., verapamil and cyclosporin A) and nucleoside transport inhibitors (i.e., dipyridamole and dilazep). In contrast, DADs (i.e., zidovudine, lamivudine, didanosine, and zalcitabine) did not significantly affect vinblastine accumulation by these cell lines. These data suggest that P-gp does not play a significant role in the renal tubular transport of DADs. Dipyridamole and dilazep, two nucleoside membrane transport inhibitors, appear to be P-gp inhibitors.
引用
收藏
页码:625 / 630
页数:6
相关论文
共 50 条
  • [21] The pharmacological role of P-glycoprotein
    Schinkel, AH
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R25 - R25
  • [22] Role of human CYP3A and P-glycoprotein on the absorption of drugs
    van de Waterbeemd, H
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 12 (01) : 1 - 1
  • [23] P-Glycoprotein Transport of Neurotoxic Pesticides
    Lacher, Sarah E.
    Skagen, Kasse
    Veit, Joachim
    Dalton, Rachel
    Woodahl, Erica L.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 355 (01): : 99 - 107
  • [24] P-GLYCOPROTEIN AND THE RENAL SECRETION OF DEOXYRIBONUCLEOSIDES
    PAN, BF
    NELSON, JA
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1994, 13 (05): : 1179 - 1188
  • [25] Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine
    Drion, N
    Lemaire, M
    Lefauconnier, JM
    Scherrmann, JM
    JOURNAL OF NEUROCHEMISTRY, 1996, 67 (04) : 1688 - 1693
  • [26] The role of mdr2 P-glycoprotein in hepatobiliary lipid transport
    Elferink, RPJO
    Tytgat, GNJ
    Groen, AK
    FASEB JOURNAL, 1997, 11 (01): : 19 - 28
  • [27] A Role for iNOS in Erastin Mediated Reduction of P-Glycoprotein Transport Activity
    Brown, Shalyn M.
    Sinha, Birandra K.
    Cannon, Ronald E.
    CANCERS, 2024, 16 (09)
  • [28] Drugs as P-glycoprotein substrates, inhibitors, and inducers
    Kim, RB
    DRUG METABOLISM REVIEWS, 2002, 34 (1-2) : 47 - 54
  • [29] INTERACTION OF DRUGS WITH P-GLYCOPROTEIN IN BRAIN CAPILLARIES
    JETTE, L
    MURPHY, GF
    LECLERC, JM
    BELIVEAU, R
    BIOCHEMICAL PHARMACOLOGY, 1995, 50 (10) : 1701 - 1709
  • [30] Molecular Modeling of P-Glycoprotein and Related Drugs
    Ilza Pajeva
    Christoph Globisch
    Romy Fleischer
    Ivanka Tsakovska
    Michael Wiese
    Medicinal Chemistry Research, 2005, 14 : 106 - 117